Download PDF
Semin Liver Dis 2015; 35(03): 207-220
DOI: 10.1055/s-0035-1562942
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Diagnosis and Assessment of NAFLD: Definitions and Histopathological Classification

Alastair D. Burt
1   Faculty of Health Sciences, The University of Adelaide, Level 2, Barr Smith South, North Terrace, Adelaide, Australia
,
Carolin Lackner
2   Department of Quantitative Pathomorphology, Institute of Pathology, Medical University of Graz, Graz, Austria
,
Dina G. Tiniakos
3   Clinical Senior Lecturer, Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Framlington Place, Newcastle upon Tyne, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
17 September 2015 (online)

    Permissions and Reprints

Abstract

Nonalcoholic fatty liver disease (NAFLD) comprises a spectrum of clinical and histopathological changes including “simple” steatosis, steatosis with inflammation, steatohepatitis, cirrhosis, and hepatocellular carcinoma. It was initially described in the context of drug-induced liver injury and acute liver disease following jejunoileal bypass surgery, but since the early 1980s it has been widely acknowledged as the hepatic manifestation of metabolic syndrome. It now represents a burgeoning public health crisis and is fast becoming the main indication for liver transplantation in some parts of the world. Its true incidence and prevalence are unknown, although estimates have been made from large imaging studies. Liver biopsy interpretation is still regarded as the gold standard for making accurate diagnoses in NAFLD, but sampling limitations are recognized. Furthermore, clear definitions for key histopathological components have been lacking, resulting in significant interobserver variations in making a diagnosis of steatohepatitis. In this review the authors consider some aspects of classification and variant forms of NAFLD such as that occurring in children. They provide an update on grading and staging systems and histopathological prognostic factors, and address the role of liver biopsy in contemporary clinical care of patients with NAFLD.

Keywords

nonalcoholic fatty liver disease - steatosis - steatohepatitis - histopathology - metabolic syndrome
 

  • References

  • 1 MacSween RN, Burt AD. Histologic spectrum of alcoholic liver disease. Semin Liver Dis 1986; 6 (3) 221-232
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Peters RL. Hepatic morphologic changes after jejunoileal bypass. Prog Liver Dis 1979; 6: 581-594
    PubMedGoogle Scholar
  • 3 Lewis D, Wainwright HC, Kew MC, Zwi S, Isaacson C. Liver damage associated with perhexiline maleate. Gut 1979; 20 (3) 186-189
    CrossrefPubMedGoogle Scholar
  • 4 Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55 (7) 434-438
    PubMedGoogle Scholar
  • 5 Addison T. Observations on fatty degeneration of the liver. Guys Hosp Rep 1836; 1: 476
    PubMedGoogle Scholar
  • 6 Rokitansky CA. Skizze der Größen und Formabweichungen der Leber. Bruchstück Med Jahrb des kaisl, königl Österr Staates 1839; Bd 29 oder neueste Folge Bd 20 Wien: 557
    PubMedGoogle Scholar
  • 7 Bartolow P. Diseases of the liver. In: Pepper W, Starr L, (eds.). A System of Practical Medicine. Vol. II. Philadelphia, PA: Lea Brothers & Co; 1885: 1050
    Google Scholar
  • 8 Statkewitsch P. Über veränderungen des muskel-und drüsengewebes sowie der herzganglien beim hungern. Arch Exper Path Pharmakol 1894; 33: 415-461
    PubMedGoogle Scholar
  • 9 Pepper W. Saccharine diabetes. Med Rec 1884; 25: 9-12
    PubMedGoogle Scholar
  • 10 Connor CL. Fatty infiltration of the liver and the development of cirrhosis in diabetes and chronic alcoholism. Am J Pathol 1938; 14 (3) 347-364 , 9
    PubMedGoogle Scholar
  • 11 Brunt EM, Neuschwander-Tetri BA, Burt AD. Fatty liver disease: Alcoholic and non-alcoholic. In: Burt AD, Portmann B, Ferrel L, (Eds.). MacSween's Pathology of the Liver. Edinburgh: Churchill Livingstone; 2012: 293-359
    CrossrefGoogle Scholar
  • 12 Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol 2014; 28 (4) 637-653
    PubMedGoogle Scholar
  • 13 Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology 2014; 147 (4) 754-764
    CrossrefPubMedGoogle Scholar
  • 14 Tandra S, Yeh MM, Brunt EM , et al; NASH Clinical Research Network (NASH CRN). Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J Hepatol 2011; 55 (3) 654-659
    CrossrefPubMedGoogle Scholar
  • 15 Yip WW, Burt AD. Alcoholic liver disease. Semin Diagn Pathol 2006; 23 (3-4) 149-160
    CrossrefPubMedGoogle Scholar
  • 16 Sahini N, Borlak J. Recent insights into the molecular pathophysiology of lipid droplet formation in hepatocytes. Prog Lipid Res 2014; 54: 86-112
    CrossrefPubMedGoogle Scholar
  • 17 Pawella LM, Hashani M, Eiteneuer E , et al. Perilipin discerns chronic from acute hepatocellular steatosis. J Hepatol 2014; 60 (3) 633-642
    PubMedGoogle Scholar
  • 18 Smagris E, BasuRay S, Li J , et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 2015; 61 (1) 108-118
    CrossrefPubMedGoogle Scholar
  • 19 Choi SS, Diehl AM. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol 2008; 19 (3) 295-300
    CrossrefPubMedGoogle Scholar
  • 20 Singhi AD, Jain D, Kakar S, Wu TT, Yeh MM, Torbenson M. Reticulin loss in benign fatty liver: an important diagnostic pitfall when considering a diagnosis of hepatocellular carcinoma. Am J Surg Pathol 2012; 36 (5) 710-715
    CrossrefPubMedGoogle Scholar
  • 21 Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94 (9) 2467-2474
    CrossrefPubMedGoogle Scholar
  • 22 Kleiner DE, Brunt EM, Van Natta M , et al; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41 (6) 1313-1321
    CrossrefPubMedGoogle Scholar
  • 23 Hall AR, Dhillon AP, Green AC , et al. Hepatic steatosis estimated microscopically versus digital image analysis. Liver Int 2013; 33 (6) 926-935
    CrossrefPubMedGoogle Scholar
  • 24 Hall AR, Green AC, Luong TV, Burroughs AK, Wyatt J, Dhillon AP. The use of guideline images to improve histological estimation of hepatic steatosis. Liver Int 2014; 34 (9) 1414-1427
    CrossrefPubMedGoogle Scholar
  • 25 Karlas T, Petroff D, Garnov N , et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS ONE 2014; 9 (3) e91987
    CrossrefPubMedGoogle Scholar
  • 26 Schwimmer JB, Middleton MS, Behling C , et al. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology 2015; 61 (6) 1887-1895
    CrossrefPubMedGoogle Scholar
  • 27 Noureddin M, Lam J, Peterson MR , et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013; 58 (6) 1930-1940
    CrossrefPubMedGoogle Scholar
  • 28 Idilman IS, Keskin O, Elhan AH, Idilman R, Karcaaltincaba M. Impact of sequential proton density fat fraction for quantification of hepatic steatosis in nonalcoholic fatty liver disease. Scand J Gastroenterol 2014; 49 (5) 617-624
    CrossrefPubMedGoogle Scholar
  • 29 Smith K. Liver disease: Kupffer cells regulate the progression of ALD and NAFLD. Nat Rev Gastroenterol Hepatol 2013; 10 (9) 503
    PubMedGoogle Scholar
  • 30 Harmon RC, Tiniakos DG, Argo CK. Inflammation in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2011; 5 (2) 189-200
    CrossrefPubMedGoogle Scholar
  • 31 Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic fatty liver disease: metabolic complications and therapeutic tools. Front Immunol 2014; 5: 177
    PubMedGoogle Scholar
  • 32 Sutti S, Jindal A, Locatelli I , et al. Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH. Hepatology 2014; 59 (3) 886-897
    CrossrefPubMedGoogle Scholar
  • 33 Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13 (4) 643-54.e1 , 9, quiz e39–e40
    CrossrefPubMedGoogle Scholar
  • 34 McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015; 62 (5) 1148-1155
    CrossrefPubMedGoogle Scholar
  • 35 Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003; 37 (5) 1202-1219
    CrossrefPubMedGoogle Scholar
  • 36 Sanyal AJ, Brunt EM, Kleiner DE , et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54 (1) 344-353
    CrossrefPubMedGoogle Scholar
  • 37 Matsuda Y, Takada A, Kanayama R, Takase S. Changes of hepatic microtubules and secretory proteins in human alcoholic liver disease. Pharmacol Biochem Behav 1983; 18 (Suppl. 01) 479-482
    CrossrefPubMedGoogle Scholar
  • 38 Schaff Z, Lapis K. Fine structure of hepatocytes during the etiology of several common pathologies. J Electron Microsc Tech 1990; 14 (3) 179-207
    CrossrefPubMedGoogle Scholar
  • 39 Gores GJ, Herman B, Lemasters JJ. Plasma membrane bleb formation and rupture: a common feature of hepatocellular injury. Hepatology 1990; 11 (4) 690-698
    CrossrefPubMedGoogle Scholar
  • 40 Caldwell S, Ikura Y, Dias D , et al. Hepatocellular ballooning in NASH. J Hepatol 2010; 53 (4) 719-723
    CrossrefPubMedGoogle Scholar
  • 41 Lackner C, Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM, Denk H. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol 2008; 48 (5) 821-828
    CrossrefPubMedGoogle Scholar
  • 42 Zatloukal K, French SW, Stumptner C , et al. From Mallory to Mallory-Denk bodies: what, how and why?. Exp Cell Res 2007; 313 (10) 2033-2049
    CrossrefPubMedGoogle Scholar
  • 43 Rangwala F, Guy CD, Lu J , et al. Increased production of sonic hedgehog by ballooned hepatocytes. J Pathol 2011; 224 (3) 401-410
    CrossrefPubMedGoogle Scholar
  • 44 Tannapfel A, Denk H, Dienes HP , et al. [Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines]. Pathologe 2010; 31 (3) 225-237
    PubMedGoogle Scholar
  • 45 Farrell GC, Chitturi S, Lau GK, Sollano JD ; Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 2007; 22 (6) 775-777
    CrossrefPubMedGoogle Scholar
  • 46 Loria P, Adinolfi LE, Bellentani S , et al; NAFLD Expert Committee of the Associazione Italiana per lo studio del Fegato. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010; 42 (4) 272-282
    CrossrefPubMedGoogle Scholar
  • 47 Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53 (2) 372-384
    CrossrefPubMedGoogle Scholar
  • 48 Chalasani N, Younossi Z, Lavine JE , et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55 (6) 2005-2023
    CrossrefPubMedGoogle Scholar
  • 49 Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25 (1) 108-111
    CrossrefPubMedGoogle Scholar
  • 50 Iturriaga H, Bunout D, Hirsch S, Ugarte G. Overweight as a risk factor or a predictive sign of histological liver damage in alcoholics. Am J Clin Nutr 1988; 47 (2) 235-238
    PubMedGoogle Scholar
  • 51 Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 2005; 42 (1) 5-13
    PubMedGoogle Scholar
  • 52 Nalbantoglu IL, Brunt EM. Role of liver biopsy in nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20 (27) 9026-9037
    PubMedGoogle Scholar
  • 53 Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20 (2) 475-485
    CrossrefPubMedGoogle Scholar
  • 54 Younossi ZM, Gramlich T, Liu YC , et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998; 11 (6) 560-565
    PubMedGoogle Scholar
  • 55 Bedossa P ; FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014; 60 (2) 565-575
    CrossrefPubMedGoogle Scholar
  • 56 Guy CD, Suzuki A, Burchette JL , et al; Nonalcoholic Steatohepatitis Clinical Research Network. Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease. Hum Pathol 2012; 43 (6) 790-800
    CrossrefPubMedGoogle Scholar
  • 57 Stumptner C, Fuchsbichler A, Heid H, Zatloukal K, Denk H. Mallory body—a disease-associated type of sequestosome. Hepatology 2002; 35 (5) 1053-1062
    CrossrefPubMedGoogle Scholar
  • 58 Ludwig J, McGill DB, Lindor KD. Review: nonalcoholic steatohepatitis. J Gastroenterol Hepatol 1997; 12 (5) 398-403
    CrossrefPubMedGoogle Scholar
  • 59 Guy CD, Suzuki A, Zdanowicz M , et al; NASH CRN. Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Hepatology 2012; 55 (6) 1711-1721
    CrossrefPubMedGoogle Scholar
  • 60 Williams R. Global challenges in liver disease. Hepatology 2006; 44 (3) 521-526
    CrossrefPubMedGoogle Scholar
  • 61 Fan JG, Peng YD. Metabolic syndrome and non-alcoholic fatty liver disease: Asian definitions and Asian studies. Hepatobiliary Pancreat Dis Int 2007; 6 (6) 572-578
    PubMedGoogle Scholar
  • 62 Fan JG, Zhu J, Li XJ , et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005; 43 (3) 508-514
    CrossrefPubMedGoogle Scholar
  • 63 Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007; 11 (7) 860-868
    CrossrefPubMedGoogle Scholar
  • 64 Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94 (3) 274-286
    CrossrefPubMedGoogle Scholar
  • 65 Gentilucci UV, Santini D, Vincenzi B, Fiori E, Picardi A, Tonini G. Chemotherapy-induced steatohepatitis in colorectal cancer patients. J Clin Oncol 2006; 24 (34) 5467 , author reply 5467–5468
    PubMedGoogle Scholar
  • 66 Raja K, Thung SN, Fiel MI, Chang C. Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use. Semin Liver Dis 2009; 29 (4) 423-428
    Article in Thieme ConnectPubMedGoogle Scholar
  • 67 Karoui M, Penna C, Amin-Hashem M , et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006; 243 (1) 1-7
    Google Scholar
  • 68 Patel V, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis 2013; 17 (4) 533-546 , vii
    CrossrefPubMedGoogle Scholar
  • 69 Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol 2009; 62 (6) 481-492
    CrossrefPubMedGoogle Scholar
  • 70 Vauthey JN, Pawlik TM, Ribero D , et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24 (13) 2065-2072
    Google Scholar
  • 71 Brunt EM, Tiniakos DG. Fatty liver disease. In: Odze RD, Goldblum JR, (Eds.). Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. 3rd ed. Philadelphia, PA: Elsevier; 2014: 1087-1114
    Google Scholar
  • 72 Thomopoulos KC, Arvaniti V, Tsamantas AC , et al. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol 2006; 18 (3) 233-237
    CrossrefPubMedGoogle Scholar
  • 73 Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol 2011; 26 (9) 1361-1367
    PubMedGoogle Scholar
  • 74 Lonardo A, Adinolfi LE, Restivo L , et al. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. World J Gastroenterol 2014; 20 (23) 7089-7103
    CrossrefPubMedGoogle Scholar
  • 75 Vallet-Pichard A, Mallet V, Pol S. Nonalcoholic fatty liver disease and HIV infection. Semin Liver Dis 2012; 32 (2) 158-166
    Article in Thieme ConnectPubMedGoogle Scholar
  • 76 Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2004; 99 (7) 1316-1320
    CrossrefPubMedGoogle Scholar
  • 77 Yatsuji S, Hashimoto E, Kaneda H, Taniai M, Tokushige K, Shiratori K. Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful?. J Gastroenterol 2005; 40 (12) 1130-1138
    CrossrefPubMedGoogle Scholar
  • 78 Czaja AJ. Autoantibody-negative autoimmune hepatitis. Dig Dis Sci 2012; 57 (3) 610-624
    CrossrefPubMedGoogle Scholar
  • 79 Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A, Vecchione R. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol 2009; 50 (2) 351-357
    CrossrefPubMedGoogle Scholar
  • 80 Híndi M, Levy C, Couto CA, Bejarano P, Mendes F. Primary biliary cirrhosis is more severe in overweight patients. J Clin Gastroenterol 2013; 47 (3) e28-e32
    CrossrefPubMedGoogle Scholar
  • 81 Nelson JE, Brunt EM, Kowdley KV ; Nonalcoholic Steatohepatitis Clinical Research Network. Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations. Hepatology 2012; 56 (5) 1730-1740
    CrossrefPubMedGoogle Scholar
  • 82 Brunt EM, Ramrakhiani S, Cordes BG , et al. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 2003; 16 (1) 49-56
    CrossrefPubMedGoogle Scholar
  • 83 Powell EE, Jonsson JR, Clouston AD. Metabolic factors and non-alcoholic fatty liver disease as co-factors in other liver diseases. Dig Dis 2010; 28 (1) 186-191
    CrossrefPubMedGoogle Scholar
  • 84 Nelson JE, Wilson L, Brunt EM , et al; Nonalcoholic Steatohepatitis Clinical Research Network. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 2011; 53 (2) 448-457
    CrossrefPubMedGoogle Scholar
  • 85 Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc 2014; 89 (1) 95-106
    CrossrefPubMedGoogle Scholar
  • 86 Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter?. Gut 2006; 55 (1) 123-130
    CrossrefPubMedGoogle Scholar
  • 87 Abenavoli L, Masarone M, Peta V , et al. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World J Gastroenterol 2014; 20 (41) 15233-15240
    CrossrefPubMedGoogle Scholar
  • 88 Bedossa P, Moucari R, Chelbi E , et al. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology 2007; 46 (2) 380-387
    CrossrefPubMedGoogle Scholar
  • 89 Bugianesi E, Salamone F, Negro F. The interaction of metabolic factors with HCV infection: does it matter?. J Hepatol 2012; 56 (Suppl. 01) S56-S65
    PubMedGoogle Scholar
  • 90 Machado MV, Cortez-Pinto H. Cell death and nonalcoholic steatohepatitis: where is ballooning relevant?. Expert Rev Gastroenterol Hepatol 2011; 5 (2) 213-222
    CrossrefPubMedGoogle Scholar
  • 91 Pais R, Rusu E, Zilisteanu D , et al. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. Eur J Intern Med 2015; 26 (1) 30-36
    CrossrefPubMedGoogle Scholar
  • 92 Day CP, James OF. Steatohepatitis: a tale of two “hits”?. Gastroenterology 1998; 114 (4) 842-845
    CrossrefPubMedGoogle Scholar
  • 93 Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52 (5) 1836-1846
    CrossrefPubMedGoogle Scholar
  • 94 Ibrahim SH, Kohli R, Gores GJ. Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr 2011; 53 (2) 131-140
    PubMedGoogle Scholar
  • 95 Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?. Aliment Pharmacol Ther 2012; 36 (9) 815-823
    PubMedGoogle Scholar
  • 96 Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol 1998; 15 (4) 246-258
    PubMedGoogle Scholar
  • 97 Loria P, Lonardo A, Carulli N. Should nonalcoholic fatty liver disease be renamed?. Dig Dis 2005; 23 (1) 72-82
    CrossrefPubMedGoogle Scholar
  • 98 Hourigan SK, Torbenson M, Tibesar E, Scheimann AO. The full spectrum of hepatic steatosis in children. Clin Pediatr (Phila) 2015; 54 (7) 635-642
    CrossrefPubMedGoogle Scholar
  • 99 Nobili V, Svegliati-Baroni G, Alisi A, Miele L, Valenti L, Vajro P. A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol 2013; 58 (6) 1218-1229
    CrossrefPubMedGoogle Scholar
  • 100 Shang XR, Song JY, Liu FH, Ma J, Wang HJ. GWAS-identified common variants with nonalcoholic fatty liver disease in chinese children. J Pediatr Gastroenterol Nutr 2015; 60 (5) 669-674
    CrossrefPubMedGoogle Scholar
  • 101 Molleston JP, Schwimmer JB, Yates KP , et al; NASH Clinical Research Network. Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J Pediatr 2014; 164 (4) 707-713.e3
    CrossrefPubMedGoogle Scholar
  • 102 Mansoor S, Yerian L, Kohli R , et al. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease. Dig Dis Sci 2015; 60 (5) 1440-1447
    CrossrefPubMedGoogle Scholar
  • 103 Nobili V, Pinzani M. Alcoholic and non-alcoholic fatty liver in adolescents: a worrisome convergence. Alcohol Alcohol 2011; 46 (5) 627-629
    CrossrefPubMedGoogle Scholar
  • 104 Schwimmer JB, Behling C, Newbury R , et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42 (3) 641-649
    CrossrefPubMedGoogle Scholar
  • 105 Nobili V, Marcellini M, Devito R , et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006; 44 (2) 458-465
    CrossrefPubMedGoogle Scholar
  • 106 Carter-Kent C, Yerian LM, Brunt EM , et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 2009; 50 (4) 1113-1120
    CrossrefPubMedGoogle Scholar
  • 107 Takahashi Y, Inui A, Fujisawa T, Takikawa H, Fukusato T. Histopathological characteristics of non-alcoholic fatty liver disease in children: comparison with adult cases. Hepatol Res 2011; 41 (11) 1066-1074
    CrossrefPubMedGoogle Scholar
  • 108 Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012; 32 (1) 3-13
    Article in Thieme ConnectPubMedGoogle Scholar
  • 109 Suzuki A, Abdelmalek MF, Schwimmer JB , et al; Nonalcoholic Steatohepatitis Clinical Research Network. Association between puberty and features of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012; 10 (7) 786-794
    CrossrefPubMedGoogle Scholar
  • 110 Swiderska-Syn M, Suzuki A, Guy CD , et al. Hedgehog pathway and pediatric nonalcoholic fatty liver disease. Hepatology 2013; 57 (5) 1814-1825
    CrossrefPubMedGoogle Scholar
  • 111 Alkhouri N, De Vito R, Alisi A , et al. Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. J Hepatol 2012; 57 (6) 1312-1318
    CrossrefPubMedGoogle Scholar
  • 112 Younossi ZM, Stepanova M, Rafiq N , et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011; 53 (6) 1874-1882
    CrossrefPubMedGoogle Scholar
  • 113 Bedossa P, Poitou C, Veyrie N , et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012; 56 (5) 1751-1759
    CrossrefPubMedGoogle Scholar
  • 114 Nonalcoholic steatohepatitis clinical research network. Hepatology 2003; 37 (2) 244
    CrossrefPubMedGoogle Scholar
  • 115 Hjelkrem M, Stauch C, Shaw J, Harrison SA. Validation of the non-alcoholic fatty liver disease activity score. Aliment Pharmacol Ther 2011; 34 (2) 214-218
    CrossrefPubMedGoogle Scholar
  • 116 Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000; 31 (1) 241-246
    CrossrefPubMedGoogle Scholar
  • 117 Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116 (6) 1413-1419
    CrossrefPubMedGoogle Scholar
  • 118 Sandrini J, Boursier J, Chaigneau J , et al. Quantification of portal-bridging fibrosis area more accurately reflects fibrosis stage and liver stiffness than whole fibrosis or perisinusoidal fibrosis areas in chronic hepatitis C. Mod Pathol 2014; 27 (7) 1035-1045
    CrossrefPubMedGoogle Scholar
  • 119 Boursier J, de Ledinghen V, Sturm N , et al; Multicentre group ANRS HC EP23 FIBROSTAR. Precise evaluation of liver histology by computerized morphometry shows that steatosis influences liver stiffness measured by transient elastography in chronic hepatitis C. J Gastroenterol 2014; 49 (3) 527-537
    CrossrefPubMedGoogle Scholar
  • 120 Levene AP, Kudo H, Armstrong MJ , et al. Quantifying hepatic steatosis - more than meets the eye. Histopathology 2012; 60 (6) 971-981
    CrossrefPubMedGoogle Scholar
  • 121 Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22 (6) 1714-1719
    CrossrefPubMedGoogle Scholar
  • 122 Pais R, Pascale A, Fedchuck L, Charlotte F, Poynard T, Ratziu V. Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Clin Res Hepatol Gastroenterol 2011; 35 (1) 23-28
    CrossrefPubMedGoogle Scholar
  • 123 Wong VW, Wong GL, Choi PC , et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59 (7) 969-974
    CrossrefPubMedGoogle Scholar
  • 124 Ekstedt M, Franzén LE, Mathiesen UL , et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44 (4) 865-873
    CrossrefPubMedGoogle Scholar
  • 125 Söderberg C, Stål P, Askling J , et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51 (2) 595-602
    CrossrefPubMedGoogle Scholar
  • 126 Brunt EM, Kleiner DE, Wilson LA , et al; NASH Clinical Research NetworkA list of members of the Nonalcoholic Steatohepatitis Clinical Research Network can be found in the Appendix. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009; 49 (3) 809-820
    CrossrefPubMedGoogle Scholar
  • 127 Gadd VL, Skoien R, Powell EE , et al. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology 2014; 59 (4) 1393-1405
    CrossrefPubMedGoogle Scholar
  • 128 Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24 (1) 3-20
    Article in Thieme ConnectPubMedGoogle Scholar
  • 129 Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003; 98 (9) 2042-2047
    CrossrefPubMedGoogle Scholar
  • 130 Fassio E, Alvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004; 40 (4) 820-826
    PubMedGoogle Scholar
  • 131 Sorrentino P, Tarantino G, Conca P , et al. Silent non-alcoholic fatty liver disease-a clinical-histological study. J Hepatol 2004; 41 (5) 751-757
    CrossrefPubMedGoogle Scholar
  • 132 Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32 (4 Pt 1) 689-692
    CrossrefPubMedGoogle Scholar
  • 133 Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004; 40 (4) 578-584
    CrossrefPubMedGoogle Scholar
  • 134 Bugianesi E, Leone N, Vanni E , et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123 (1) 134-140
    CrossrefPubMedGoogle Scholar
  • 135 Hashimoto E, Yatsuji S, Tobari M , et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 2009; 44 (Suppl 19): 89-95
    CrossrefPubMedGoogle Scholar
  • 136 Ekstedt M, Hagström H, Nasr P , et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61 (5) 1547-1554
    CrossrefPubMedGoogle Scholar
  • 137 Torres DM, Harrison SA. Nonalcoholic fatty liver disease: fibrosis portends a worse prognosis. Hepatology 2015; 61 (5) 1462-1464
    CrossrefPubMedGoogle Scholar
  • 138 Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol 2014; 20 (36) 12956-12980
    CrossrefPubMedGoogle Scholar
  • 139 Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 2011; 54 (1) 133-144
    CrossrefPubMedGoogle Scholar
  • 140 Guy CD, Suzuki A, Abdelmalek MF, Burchette JL, Diehl AM ; NASH CRN. Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity. Hepatology 2015; 61 (1) 98-107
    CrossrefPubMedGoogle Scholar
  • 141 Starmann J, Fälth M, Spindelböck W , et al. Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. PLoS ONE 2012; 7 (10) e46584
    CrossrefPubMedGoogle Scholar
  • 142 Scuric Z, Stain SC, Anderson WF, Hwang JJ. New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma. Hepatology 1998; 27 (4) 943-950
    CrossrefPubMedGoogle Scholar
  • 143 Yoshitake H, Takahashi M, Ishikawa H , et al. Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer. Int J Gynecol Cancer 2007; 17 (6) 1300-1306
    CrossrefPubMedGoogle Scholar
  • 144 Heringlake S, Hofdmann M, Fiebeler A, Manns MP, Schmiegel W, Tannapfel A. Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours. J Hepatol 2010; 52 (2) 220-227
    CrossrefPubMedGoogle Scholar
  • 145 Lefkowitch JH, Haythe JH, Regent N. Kupffer cell aggregation and perivenular distribution in steatohepatitis. Mod Pathol 2002; 15 (7) 699-704
    CrossrefPubMedGoogle Scholar
  • 146 Park JW, Jeong G, Kim SJ, Kim MK, Park SM. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol 2007; 22 (4) 491-497
    CrossrefPubMedGoogle Scholar
  • 147 Richardson MM, Jonsson JR, Powell EE , et al. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 2007; 133 (1) 80-90
    CrossrefPubMedGoogle Scholar
  • 148 Lonardo A, Ballestri S, Targher G, Loria P. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2015; 9 (5) 629-650
    CrossrefPubMedGoogle Scholar
  • 149 Rafiq N, Bai C, Fang Y , et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7 (2) 234-238
    CrossrefPubMedGoogle Scholar
  • 150 Browning JD, Szczepaniak LS, Dobbins R , et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40 (6) 1387-1395
    CrossrefPubMedGoogle Scholar
  • 151 Bedogni G, Miglioli L, Masutti F , et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007; 46 (5) 1387-1391
    CrossrefPubMedGoogle Scholar
  • 152 Lonardo A, Bellini M, Tartoni P, Tondelli E. The bright liver syndrome. Prevalence and determinants of a “bright” liver echopattern. Ital J Gastroenterol Hepatol 1997; 29 (4) 351-356
    PubMedGoogle Scholar
  • 153 Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27 (2) 142-149
    CrossrefPubMedGoogle Scholar
  • 154 Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 2009; 13 (4) 511-531
    CrossrefPubMedGoogle Scholar
  • 155 Bellentani S, Bedogni G, Miglioli L, Tiribelli C. The epidemiology of fatty liver. Eur J Gastroenterol Hepatol 2004; 16 (11) 1087-1093
    CrossrefPubMedGoogle Scholar
  • 156 Targher G, Bertolini L, Padovani R , et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30 (5) 1212-1218
    CrossrefPubMedGoogle Scholar
  • 157 Jimba S, Nakagami T, Takahashi M , et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005; 22 (9) 1141-1145
    CrossrefPubMedGoogle Scholar
  • 158 Williams CD, Stengel J, Asike MI , et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140 (1) 124-131
    CrossrefPubMedGoogle Scholar
  • 159 Williamson RM, Price JF, Glancy S , et al; Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 2011; 34 (5) 1139-1144
    CrossrefPubMedGoogle Scholar
  • 160 Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12 (5) 1106-1110
    CrossrefPubMedGoogle Scholar
  • 161 Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42 (1) 132-138
    CrossrefPubMedGoogle Scholar
  • 162 Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol 2014; 5 (4) 277-286
    CrossrefPubMedGoogle Scholar
  • 163 Kwok R, Tse YK, Wong GL , et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease—the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther 2014; 39 (3) 254-269
    CrossrefPubMedGoogle Scholar
  • 164 Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011; 259 (3) 749-756
    CrossrefPubMedGoogle Scholar
  • 165 Angulo P, Hui JM, Marchesini G , et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45 (4) 846-854
    CrossrefPubMedGoogle Scholar
  • 166 Wong VW, Wong GL, Chim AM , et al. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol 2008; 103 (7) 1682-1688
    PubMedGoogle Scholar
  • 167 McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59 (9) 1265-1269
    CrossrefPubMedGoogle Scholar
  • 168 Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol 2014; 5 (3) 211-218
    CrossrefPubMedGoogle Scholar
  • 169 Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 2013; 58 (5) 1007-1019
    CrossrefPubMedGoogle Scholar
  • 170 Leandro G, Mangia A, Hui J , et al; HCV Meta-Analysis (on) Individual Patients' Data Study Group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130 (6) 1636-1642
    CrossrefPubMedGoogle Scholar
  • 171 Petta S, Cammà C, Di Marco V , et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver Int 2011; 31 (4) 507-515
    CrossrefPubMedGoogle Scholar
  • 172 Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001; 21 (4) 266-271
    CrossrefPubMedGoogle Scholar
  • 173 Farrell GC, Liddle C. Drugs and the liver updated, 2002. Semin Liver Dis 2002; 22 (2) 109-113
    PubMedGoogle Scholar
  • 174 Nascimbeni F, Pais R, Bellentani S , et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013; 59 (4) 859-871
    CrossrefPubMedGoogle Scholar
  • 175 Boursier J, Chaigneau J, Roullier V , et al; Study group UNAM-METABOL. Steatosis degree, measured by morphometry, is linked to other liver lesions and metabolic syndrome components in patients with NAFLD. Eur J Gastroenterol Hepatol 2011; 23 (11) 974-981
    Google Scholar